On Tuesday, investors hope to learn Pfizer Inc’s plans for what could be a once in a generation cash infusion from COVID-19 treatments and vaccines in 2022. Some drugmakers are looking to spend on potential acquisitions. According to Chief Executive Albert… Read More ›
Drugmakers, including Gilead Sciences Inc, Bristol-Myers Squibb Co, and Biogen Inc have hiked their U.S. list prices on more than 50 drugs, according to data analyzed by 3 Axis Advisors, a healthcare research firm. On Tuesday, there were media reports… Read More ›
manageria.biz 